2021年11月23日简报:中国研发的中和抗体能降低78%的住院和死亡率,有望年底上市;美前卫生局长警告称美新冠病例今冬或激增

2021-11-23 MedSci整理 MedSci整理

截至北京时间2021年11月23日7时01分,Worldometers世界实时统计数据显示,全球累计确诊新冠肺炎(COVID-19)病例超过2亿5830万例,新增412,810例,达到258,304,

截至北京时间2021年11月23日7时01分,Worldometers世界实时统计数据显示,全球累计确诊新冠肺炎COVID-19)病例超过2亿5830万例,新增412,810例,达到258,304,629例。累计死亡病例517.3万例,达到5,173,286例。新增死亡为4,855例。康复为233,734,474例,重症和危重症病人达到80,348例;全球新冠确诊病例超过100万例的国家达36个,112个国家病例超10万例。昨日报道:2021年11月22日简报:科学研究表明戴口罩和洗手是预防新冠病毒感染最有效的方式;法国再现新冠变种B.1.X或B.1.640;新加坡要求拒打疫苗者自付新冠治疗费

法国总理卡斯泰新冠病毒检测呈阳性

法国总理府当地时间22日晚向法新社表示,法国总理卡斯泰当天接受的新冠病毒检测结果呈阳性。当天早些时候,卡斯泰因为其11岁的女儿新冠病毒检测呈阳性而被确定为密接者。

法国总理府表示,接下来卡斯泰的行程安排将作出相应调整,以便于他在10天的隔离期内继续履行总理职责。

今年6月18日,卡斯泰已完成两剂阿斯利康新冠疫苗的接种。

匈牙利累计新冠确诊病例超百万

匈牙利新冠疫情防控中心22日发布的数据显示,该国新增新冠确诊病例27209例,累计确诊病例过百万例,达1025697例;新增死亡病例392例,累计死亡33172例。

据统计,匈牙利累计新冠确诊病例数从5月20日超80万到11月8日超90万历时170多天,从90万增至100万则仅用14天。6月中旬至8月中旬,匈牙利疫情曾有所放缓,每日新增病例数不到100例。但从10月中旬开始,疫情再次加剧。匈牙利第四波疫情来势凶猛,近日单日新增确诊病例数连续破万。

匈牙利科学院教授、病毒学家鲁什沃伊·米克洛什对新华社记者说,德尔塔毒株更具传染性、室内戴口罩等限制措施实施太晚、近期举行大型群众集会等,是导致该国第四波疫情迅速抬头的原因。

匈牙利总理欧尔班19日在公共广播电台接受每周例行采访时说,匈牙利正深陷第四波新冠疫情中,“艰难的部分还在后头”。

德国卫生部长:未接种疫苗的人可能在冬天全部感染新冠

美联社11月22日报道,德国卫生部长周一表示,新冠病例的迅速增加意味着,该国所有未接种疫苗的人很可能在冬季结束时感染。

据报道,德国卫生部长延斯·斯帕恩(Jens Spahn)敦促德国人接种疫苗,并表示如果他们的第一轮接种是在6个月前进行的,则要注射加强针,以减少严重疾病的风险。斯帕恩在柏林对记者说:“今年冬天结束时,德国或几乎所有人接种疫苗、康复、或所有人死亡。”他承认有些人认为观点显得愤世嫉俗。但他说:“这是事实。对于高度传染性德尔塔毒株,这种情况非常、非常有可能。这就是为什么我们如此紧急地建议进行疫苗接种。”

报道称,德国预计欧盟将在本周末批准针对5-11岁儿童接种新冠疫苗。而学龄儿童是该国感染率最高的人群之一。

中国研发的中和抗体能降低78%的住院和死亡率,有望12月底前获批附条件上市

清华大学、深圳市第三人民医院和腾盛博药开启联合研发。基于国内一期临床试验数据的支持,2020年12月,BRII-196和BRII-198抗体组合药物顺利进入由美国国立卫生研究院发起的新冠药物临床研究平台,开启了高标准、严要求的国际多中心随机、双盲、对照二期和三期临床试验。在4大洲、6个国家、111个临床试验机构进行的837例新冠肺炎患者三期临床试验结果显示,抗体组合药物能够降低78%的住院和死亡率,且给药组在治疗28天后实现零死亡,对照组8例死亡。

对于那些确诊时间较长(10天以内)、病情被“拖延”、病情相对较重的患者治疗效果仍非常明显。此外,经过基因改造,该药半衰期是普通抗体的2—3倍,在体内有效作用时间可长达数月。

据介绍,目前BRII-196和BRII-198联合用药有望实现在我国附条件批准上市与美国紧急使用的同步。

这也是目前我国进展最快的抗体药物,有望12月底前获得批准附条件上市。与欧美已获批紧急使用的新冠抗体药相比,该药是唯一进行了变异株感染者治疗效果评估并获得数据的。

澳门:下调新冠灭活疫苗适用年龄至3岁

澳门新型冠状病毒感染应变协调中心(下称应变协调中心)周一宣布,根据第179/2021号行政长官批示,新型冠状病毒的灭活疫苗适用人群,由年满12岁下调至年满3岁。应变协调中心又表示,有关批示明日(11月23日)生效,家长或其他监护人可由即日起开始,可为相关人士预约接种,同时亦提醒未满18岁人士接种新型冠状病毒疫苗,须取得其家长或其他监护人同意。

默克尔:德国疫情又到最严重时刻

德国看守总理默克尔周一在与基民盟领导层交流时表示,目前德国疫情状态正处于“高度戏剧化”的状态,并警告称如果第四波疫情不能被打断,医院很快将会人满为患。默克尔同时也表示,该国需要采取更严格的防控措施。

同时据媒体报道,由于疫情数持续处于高位,方便又便宜的居家检测套装也出现了供应紧张。德国主流连锁药店甚至暂时出现了线上断货的情况。

澳大利亚将允许已接种疫苗的留学生入境

据媒体报道,澳大利亚从今年12月1日起将允许已完成疫苗免疫的有效签证持有人入境,同时不需要申请豁免程序。受到新规影响的人群除了留学生外,还包括有经验的工作人群等。此外日本、韩国已完成疫苗接种的一般国民也将被允许入境。

澳大利亚超10万人示威反对防疫措施

综合澳大利亚新闻网、“今日俄罗斯”(RT)等媒体报道,抗议者当地时间20日涌上澳大利亚各大城市街道举行“为自由”集会,反对澳政府多项防疫措施,包括封锁、疫苗授权以及扩大政府防疫权力等相关提议。

美前卫生局长警告称美新冠病例今冬或激增

根据Worldometer实时统计数据,截至北京时间11月22日6时30分左右,美国累计确诊新冠肺炎病例48578722例,累计死亡病例793607例。与前一日6时30分数据相比,美国新增确诊病例26138例,新增死亡病例137例。

据美国《国会山报》20日报道,美国前卫生局局长杰罗姆·亚当斯预计,接下来几周美国民众聚集过节可能导致新冠疫情出现“冬季激增”。亚当斯在采访中说,“新冠病例的冬季激增几乎是必然,关键在于严重程度。”他认为美国民众对于新冠疫情的现状有些“乐观”了,并警示人们要在感恩节假期期间加强防疫。

巴西新增5126例确诊病例 累计确诊病例2201万例

据巴西卫生部官网最新数据,截至当地时间11月21日,巴西单日新增新冠肺炎确诊病例5126例,累计确诊病例22017276例;单日新增死亡病例72例,累计死亡612659例。

英国新增超4万例确诊病例 累计确诊病例980万例

当地时间11月21日,英国卫生和社会保障部公布最新疫情数据,过去24小时英国新增新冠肺炎确诊病例40004例,累计确诊9845492例;新增死亡病例61例,累计死亡143927例。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1770522, encodeId=76871e70522fc, content=<a href='/topic/show?id=05fe2665508' target=_blank style='color:#2F92EE;'>#体能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26655, encryptionId=05fe2665508, topicName=体能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80ae38174281, createdName=liubm568, createdTime=Sun May 08 22:24:17 CST 2022, time=2022-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764284, encodeId=08181e642841f, content=<a href='/topic/show?id=967b66e9727' target=_blank style='color:#2F92EE;'>#激增#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66797, encryptionId=967b66e9727, topicName=激增)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=faa237702659, createdName=ms1756883563247400, createdTime=Sun Jul 17 07:24:17 CST 2022, time=2022-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300501, encodeId=dae01300501d7, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Wed Nov 24 22:24:17 CST 2021, time=2021-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073117, encodeId=296c10e311777, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=430b4201824, createdName=13d789bam70暂无昵称, createdTime=Tue Nov 23 10:00:16 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073106, encodeId=82ef10e3106ae, content=究人员还分析了健康生活方式的潜在, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Tue Nov 23 09:30:52 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073094, encodeId=7ba010e3094c4, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2575728255, createdName=ms4000000296714113, createdTime=Tue Nov 23 08:41:06 CST 2021, time=2021-11-23, status=1, ipAttribution=)]
    2022-05-08 liubm568
  2. [GetPortalCommentsPageByObjectIdResponse(id=1770522, encodeId=76871e70522fc, content=<a href='/topic/show?id=05fe2665508' target=_blank style='color:#2F92EE;'>#体能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26655, encryptionId=05fe2665508, topicName=体能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80ae38174281, createdName=liubm568, createdTime=Sun May 08 22:24:17 CST 2022, time=2022-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764284, encodeId=08181e642841f, content=<a href='/topic/show?id=967b66e9727' target=_blank style='color:#2F92EE;'>#激增#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66797, encryptionId=967b66e9727, topicName=激增)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=faa237702659, createdName=ms1756883563247400, createdTime=Sun Jul 17 07:24:17 CST 2022, time=2022-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300501, encodeId=dae01300501d7, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Wed Nov 24 22:24:17 CST 2021, time=2021-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073117, encodeId=296c10e311777, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=430b4201824, createdName=13d789bam70暂无昵称, createdTime=Tue Nov 23 10:00:16 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073106, encodeId=82ef10e3106ae, content=究人员还分析了健康生活方式的潜在, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Tue Nov 23 09:30:52 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073094, encodeId=7ba010e3094c4, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2575728255, createdName=ms4000000296714113, createdTime=Tue Nov 23 08:41:06 CST 2021, time=2021-11-23, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1770522, encodeId=76871e70522fc, content=<a href='/topic/show?id=05fe2665508' target=_blank style='color:#2F92EE;'>#体能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26655, encryptionId=05fe2665508, topicName=体能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80ae38174281, createdName=liubm568, createdTime=Sun May 08 22:24:17 CST 2022, time=2022-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764284, encodeId=08181e642841f, content=<a href='/topic/show?id=967b66e9727' target=_blank style='color:#2F92EE;'>#激增#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66797, encryptionId=967b66e9727, topicName=激增)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=faa237702659, createdName=ms1756883563247400, createdTime=Sun Jul 17 07:24:17 CST 2022, time=2022-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300501, encodeId=dae01300501d7, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Wed Nov 24 22:24:17 CST 2021, time=2021-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073117, encodeId=296c10e311777, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=430b4201824, createdName=13d789bam70暂无昵称, createdTime=Tue Nov 23 10:00:16 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073106, encodeId=82ef10e3106ae, content=究人员还分析了健康生活方式的潜在, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Tue Nov 23 09:30:52 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073094, encodeId=7ba010e3094c4, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2575728255, createdName=ms4000000296714113, createdTime=Tue Nov 23 08:41:06 CST 2021, time=2021-11-23, status=1, ipAttribution=)]
    2021-11-24 lqvr
  4. [GetPortalCommentsPageByObjectIdResponse(id=1770522, encodeId=76871e70522fc, content=<a href='/topic/show?id=05fe2665508' target=_blank style='color:#2F92EE;'>#体能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26655, encryptionId=05fe2665508, topicName=体能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80ae38174281, createdName=liubm568, createdTime=Sun May 08 22:24:17 CST 2022, time=2022-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764284, encodeId=08181e642841f, content=<a href='/topic/show?id=967b66e9727' target=_blank style='color:#2F92EE;'>#激增#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66797, encryptionId=967b66e9727, topicName=激增)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=faa237702659, createdName=ms1756883563247400, createdTime=Sun Jul 17 07:24:17 CST 2022, time=2022-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300501, encodeId=dae01300501d7, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Wed Nov 24 22:24:17 CST 2021, time=2021-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073117, encodeId=296c10e311777, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=430b4201824, createdName=13d789bam70暂无昵称, createdTime=Tue Nov 23 10:00:16 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073106, encodeId=82ef10e3106ae, content=究人员还分析了健康生活方式的潜在, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Tue Nov 23 09:30:52 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073094, encodeId=7ba010e3094c4, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2575728255, createdName=ms4000000296714113, createdTime=Tue Nov 23 08:41:06 CST 2021, time=2021-11-23, status=1, ipAttribution=)]
    2021-11-23 13d789bam70暂无昵称

    学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1770522, encodeId=76871e70522fc, content=<a href='/topic/show?id=05fe2665508' target=_blank style='color:#2F92EE;'>#体能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26655, encryptionId=05fe2665508, topicName=体能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80ae38174281, createdName=liubm568, createdTime=Sun May 08 22:24:17 CST 2022, time=2022-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764284, encodeId=08181e642841f, content=<a href='/topic/show?id=967b66e9727' target=_blank style='color:#2F92EE;'>#激增#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66797, encryptionId=967b66e9727, topicName=激增)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=faa237702659, createdName=ms1756883563247400, createdTime=Sun Jul 17 07:24:17 CST 2022, time=2022-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300501, encodeId=dae01300501d7, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Wed Nov 24 22:24:17 CST 2021, time=2021-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073117, encodeId=296c10e311777, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=430b4201824, createdName=13d789bam70暂无昵称, createdTime=Tue Nov 23 10:00:16 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073106, encodeId=82ef10e3106ae, content=究人员还分析了健康生活方式的潜在, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Tue Nov 23 09:30:52 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073094, encodeId=7ba010e3094c4, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2575728255, createdName=ms4000000296714113, createdTime=Tue Nov 23 08:41:06 CST 2021, time=2021-11-23, status=1, ipAttribution=)]
    2021-11-23 查查佳佳

    究人员还分析了健康生活方式的潜在

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1770522, encodeId=76871e70522fc, content=<a href='/topic/show?id=05fe2665508' target=_blank style='color:#2F92EE;'>#体能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26655, encryptionId=05fe2665508, topicName=体能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80ae38174281, createdName=liubm568, createdTime=Sun May 08 22:24:17 CST 2022, time=2022-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764284, encodeId=08181e642841f, content=<a href='/topic/show?id=967b66e9727' target=_blank style='color:#2F92EE;'>#激增#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66797, encryptionId=967b66e9727, topicName=激增)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=faa237702659, createdName=ms1756883563247400, createdTime=Sun Jul 17 07:24:17 CST 2022, time=2022-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300501, encodeId=dae01300501d7, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Wed Nov 24 22:24:17 CST 2021, time=2021-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073117, encodeId=296c10e311777, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=430b4201824, createdName=13d789bam70暂无昵称, createdTime=Tue Nov 23 10:00:16 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073106, encodeId=82ef10e3106ae, content=究人员还分析了健康生活方式的潜在, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Tue Nov 23 09:30:52 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073094, encodeId=7ba010e3094c4, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2575728255, createdName=ms4000000296714113, createdTime=Tue Nov 23 08:41:06 CST 2021, time=2021-11-23, status=1, ipAttribution=)]
    2021-11-23 ms4000000296714113

    学习

    0

相关资讯

2021年11月11日简报:全球整体疫情不断回升;新冠mRNA疫苗作为加强针效果很好,国内mRNA疫苗开始加强针临床试验

截至北京时间2021年11月11日8时01分,Worldometers世界实时统计数据显示,全球累计确诊新冠肺炎(COVID-19)病例超过2亿5206万例,新增502,254例,达到252,066,

美国发起一项中草药治疗COVID-19临床试验,目前已启动

钟南山院士领衔开展的一项中国多中心、随机对照、开放标签临床研究,纳入了284位COVID-19确诊患者,在常规治疗基础上对其中142位同时给予以《伤寒论》经方麻杏石甘汤为基础制成的连花清瘟胶囊(连翘、

2021年11月22日简报:科学研究表明戴口罩和洗手是预防新冠病毒感染更有效的方式;法国再现新冠变种B.1.X或B.1.640;新加坡要求拒打疫苗者自付新冠治疗费

截至北京时间2021年11月22日7时01分,Worldometers世界实时统计数据显示,全球累计确诊新冠肺炎(COVID-19)病例超过2亿5739万例,新增467,308例,达到257,393,

2021年11月16日简报:国内下一步将推出更优加强免疫组合;国内已经有13款新冠疫苗进入了临床三期;新加坡12岁及以上人口新冠疫苗接种率超94%

截至北京时间2021年11月16日7时01分,Worldometers世界实时统计数据显示,全球累计确诊新冠肺炎(COVID-19)病例超过2亿5450万例,新增387,086例,达到254,500,

2021年11月20日简报:国内本轮疫情基本得到控制;新冠病毒在美国白尾鹿间爆炸式传播,最早可能是2019年;盖茨预测全球疫情明年夏天或迎拐点

截至北京时间2021年11月20日7时01分,Worldometers世界实时统计数据显示,全球累计确诊新冠肺炎(COVID-19)病例超过2亿5691万例,新增583,903例,达到256,911,

一种常见抗抑郁药可降低新冠死亡风险,接种疫苗无法阻止新冠病毒在家庭中传播:新冠研究一周进展

近日,发表于《自然·微生物学》(Nature Microbiology)的一项研究指出,感染新冠病毒10个月后抗体仍留在人体内。